Affordable Housing Project, Lawsuit Settlement, Drug Review, and Earnings Release Schedules - Research Reports on UnitedHealth, Bristol-Myers, Boston Scientific, Abbott and Illumina

NEW YORK, October 14, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding UnitedHealth Group Inc. (NYSE: UNH), Bristol-Myers Squibb Company (NYSE: BMY), Boston Scientific Corporation (NYSE: BSX), Abbott Laboratories (NYSE: ABT) and Illumina Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7151-100free.

--
UnitedHealth Group Inc. Research Reports
On October 9, 2014, UnitedHealth Group Inc. (UnitedHealth) informed that its subsidiary UnitedHealthcare is investing $5.1 million to help finance and build Walnut Avenue Apartments, which is an affordable-housing community in Boston's Jamaica Plain neighborhood. The Company informed that this investment is a part of its $175 million initiative to build affordable housing that helps people who need assistance live healthier lives. "Expanding access to affordable housing is important in breaking the cycle of homelessness and poverty, and helping people live healthier lives," said Stephen Farrell, CEO, UnitedHealthcare of New England. The full research reports on UnitedHealth are available to download free of charge at:

http://www.analystsreview.com/Oct-14-2014/UNH/report.pdf

--
Bristol-Myers Squibb Company Research Reports
On October 8, 2014, Bristol-Myers Squibb Company (Bristol-Myers) announced that it has resolved all the pending U.S. patent litigation relating to efavirenz - an active ingredient contained in its Sustiva and Atripla products. The Company also believes that loss of exclusivity in the U.S. for efavirenz should not occur until December 2017. The Company informed that Atripla is currently the No.1 prescribed U.S. regimen in its category, with over 8 million prescriptions written since its launch in 2006. The full research reports on Bristol-Myers are available to download free of charge at:

http://www.analystsreview.com/Oct-14-2014/BMY/report.pdf

--
Boston Scientific Corporation Research Reports
On October 8, 2014, Boston Scientific Corporation (Boston Scientific) announced that the U.S. Food and Drug Administration's (FDA) advisory panel has voted in favor of the Company's WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device after reviewing updated data and analysis. According to the Company, the Panel also voted that there is reasonable assurance that the Device is safe and agreed that it would provide a much needed alternative to long-term anticoagulation for some patients. The Advisory Panel comments and recommendations will be taken into account by FDA while reviewing the WATCHMAN Device application. "Today's recommendation by the Panel is another step toward making this innovative technology available to high risk patients with non-valvular atrial fibrillation who are eligible for warfarin, but who have reasons to seek an alternative to long-term therapy," said Kenneth Stein, M.D., Chief Medical Officer, Rhythm Management, Boston Scientific. The full research reports on Boston Scientific are available to download free of charge at:

http://www.analystsreview.com/Oct-14-2014/BSX/report.pdf

--
Abbott Laboratories Research Reports
On October 1, 2014, Abbott Laboratories (Abbott) reported that it will announce its Q3 2014 financial results on Wednesday, October 22, 2014, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8:00 a.m. CT (9:00 a.m. ET), and will be accessible through Abbott's Investor Relations website. According to Bloomberg Businessweek, analysts on average expect the Company to report Q3 2014 EPS of $0.59 on revenue of $5.6 billion. The full research reports on Abbott are available to download free of charge at:

http://www.analystsreview.com/Oct-14-2014/ABT/report.pdf

--
Illumina Inc. Research Reports
On October 6, 2014, Illumina Inc. (Illumina) announced that it will report Q3 2014 financial results following the close of market on October 20, 2014. On the same day, Jay Flatley, CEO, Francis deSouza, President, and Marc Stapley, Senior Vice President and CFO, will host a conference call with analysts, investors, and other interested parties at 2:00 p.m. PT (5:00 p.m. ET) to discuss financial and operating results. On average, analysts polled by Bloomberg Businessweek expect Illumina to report Q3 2014 EPS at $0.56, which is below the Company's Q2 2014 net income per share of $0.57. The full research reports on Illumina are available to download free of charge at:

http://www.analystsreview.com/Oct-14-2014/ILMN/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review